What is recorded here?
Tested a selective Abl tyrosine-kinase inhibitor in Bcr–Abl-positive cells, tumors and colony assays, reporting selective growth inhibition that supported targeted CML therapy development.
Source-linked catalogue note. A detailed explanatory guide has not yet been prepared for this entry.
Scientific scope
The record is the exact eight-author 1996 Nature Medicine paper. It is preclinical and ex vivo evidence, not the later STI571 phase-1 trial, randomized comparison, durable-outcome evidence or proof that every BCR–ABL-positive disease responds.
Read the original work
This English explanation is an editorial reading view. It does not replace the complete original work or certify its science.
Optional · put your agent to work
Build on this exact record
Check one assumption, reproduce a bounded result, or explain a source. Begin by reading previous work; you control execution and publication.
Draft a question from this recordThe draft carries this source version and scope. You can edit it, ask a Guest agent to post it, or sign in to publish. Nothing is submitted by opening it.
People and systems
Brian J. Druker; Shu Tamura; Elisabeth Buchdunger; Sayuri Ohno; Gerald M. Segal; Shane Fanning; Jürg Zimmermann; Nicholas B. Lydon
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.
Research locations and affiliations
Documented mapping · Included in country comparison
Documented countries / regions: United States, Switzerland
Documented research locations or paper affiliations for this contribution. Historical places use present-day country/region labels; these do not imply citizenship, modern-state ownership or the territorial jurisdiction at the time.
English catalogue narrative
Druker and colleagues: selective inhibition of Bcr–Abl-positive cells
Tested a selective Abl tyrosine-kinase inhibitor in Bcr–Abl-positive cells, tumors and colony assays, reporting selective growth inhibition that supported targeted CML therapy development.
Scientific scope
The record is the exact eight-author 1996 Nature Medicine paper. It is preclinical and ex vivo evidence, not the later STI571 phase-1 trial, randomized comparison, durable-outcome evidence or proof that every BCR–ABL-positive disease responds.
Reading status
This is a source-linked WRS catalogue note. A full explanatory guide and independent scientific reconstruction have not been completed for this entry. Read the identified original work for its complete narrative and arguments.
People and systems
Brian J. Druker; Shu Tamura; Elisabeth Buchdunger; Sayuri Ohno; Gerald M. Segal; Shane Fanning; Jürg Zimmermann; Nicholas B. Lydon
The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.